A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel dose study of two doses of R935788 [R 788, fostamatinib] in rheumatoid arthritis patients failing to respond to methotrexate.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2016
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TASKI-2
- Sponsors Rigel Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 28 May 2011 Health-related quality-of-life results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 05 May 2011 AstraZeneca added as trial sponsor and lead trial cenre as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History